Volas G H, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A
Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey 17033, USA.
Cancer. 1996 Jul 15;78(2):267-72. doi: 10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U.
Recently, the extracellular domain of the c-erbB-2 oncogene product (HER-2/neu) has been reported to be elevated in the serum of one-fourth of patients with metastatic breast carcinoma. The role of serum c-erbB-2 as a tumor marker, however, is still poorly defined. The purpose of this study was to evaluate the utility of serial serum c-erbB-2 levels as a tumor marker in patients with metastatic breast carcinoma.
c-erbB-2 levels in the sera of patients with breast carcinoma were determined by an enzyme immunoassay that detects the extracellular domain of c-erbB-2. Serum c-erbB-2 levels were evaluated prior to treatment as well as throughout the course of treatment with second-line hormonal therapy employing either megestrol acetate or fadrozole, an experimental aromatase inhibitor.
Fifty-eight of 300 patients (19.3%) had elevated pretreatment serum c-erbB-2 levels. Of these 58 patients with elevated pretreatment c-erbB-2, 48 had more than 1 visit which enabled us to quantitate serial c-erbB-2 levels throughout the course of treatment. Of these 48 patients, 28 (58.3%) had serial c-erbB-2 values that correlated with the clinical course.
Serial serum c-erbB-2 levels did not show a high overall correlation with the clinical course in this group of patients with metastatic breast carcinoma treated with second-line hormonal therapy.
最近，据报道，四分之一的转移性乳腺癌患者血清中c-erbB-2癌基因产物（HER-2/neu）的细胞外结构域水平升高。然而，血清c-erbB-2作为肿瘤标志物的作用仍未明确界定。本研究的目的是评估转移性乳腺癌患者血清c-erbB-2水平连续检测作为肿瘤标志物的实用性。
采用酶免疫分析法检测乳腺癌患者血清中c-erbB-2的细胞外结构域水平，从而测定血清c-erbB-2水平。在治疗前以及使用醋酸甲地孕酮或实验性芳香化酶抑制剂法倔唑进行二线激素治疗的整个过程中，对血清c-erbB-2水平进行评估。
300例患者中有58例（19.3%）治疗前血清c-erbB-2水平升高。在这58例治疗前c-erbB-2水平升高的患者中，48例有不止一次就诊记录，这使我们能够在整个治疗过程中对血清c-erbB-2水平进行定量检测。在这48例患者中，28例（58.3%）血清c-erbB-2值与临床病程相关。
在这组接受二线激素治疗的转移性乳腺癌患者中，血清c-erbB-2水平连续检测结果与临床病程的总体相关性不高。
